Research Article

Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer

Miaomiao Gou, Tongtong Qu, Zhikuan Wang, Huan Yan, Yanhai Si, Yong Zhang, and Guanghai Dai

1Medical Oncology Department, The First Medical Center, Chinese PLA General Hospital, Fuxing Road 28, Haidian District, Beijing, China 100853
2Medical Oncology Department, The Second Medical Center, Chinese PLA General Hospital, Fuxing Road 28, Haidian District, Beijing, China 100853

Correspondence should be addressed to Yong Zhang; yongzhshd@163.com and Guanghai Dai; daigh60@sohu.com

Received 8 October 2021; Accepted 24 November 2021; Published 28 December 2021

Academic Editor: Qiang Zhang

Copyright © 2021 Miaomiao Gou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background and Aims. Biomarkers for systemic inflammation have been introduced into clinical practice for risk-rating in cancer patients’ treatment. This study is aimed at confirming the prognostic role of the neutrophil-to-lymphocyte ratio (NLR) as an effective biomarker for patients with metastatic gastric cancer (MGC) receiving anti-PD-1 agents.

Method. Patients with MGC who received anti-PD-1 treatment at the Chinese PLA General Hospital between January 2016 and November 2020 were reviewed. The study analyzed the association of NLR and overall survival (OS) or progression-free survival (PFS) and antitumor response rate with PD-1 inhibitors.

Results. 137 patients were included in the final analysis. The area under the curve value of NLR for 6-month OS was 0.71. The best cut-off value for NLR was 3.23. NLR < 3.23 was associated with longer OS (HR = 0.38, 95% CI, 0.26-0.57, p < 0.001) and PFS (HR = 0.42, 95% CI, 0.29-0.62, p < 0.001) in patients with MGC. No significant difference was observed in the objective response rate (ORR) (35.8% vs. 28.6%, p = 0.377) and disease control rate (DCR) (86.4% vs. 78.6%, p = 0.229) in the NLR < 3.23 group and in the NLR ≥ 3.23 group, respectively. Univariate analysis and multivariate analysis found that NLR was an independent prognosis biomarker for PFS and OS.

Conclusions. Pretreatment elevated NLR was significantly associated with inferior PFS and OS in patients with MGC who received anti-PD-1 inhibitors. Clinicians need to consider patients with elevated NLR for decisions on immunotherapy strategy.

1. Introduction

Gastric cancer (GC) is the second most common cause of death amongst cancers, according to the statistics of 2015 in China [1]. The standard of care for patients with her-2 negative metastatic gastric cancer (MGC) is a double or triple regimen of chemotherapy [2]. The overall survival for MGC is poor, with a mean survival of 12-14 months [3]. Immune checkpoint inhibitors (ICI) have shown promising antitumor activity in a variety of cancers such as melanoma [4], non-small lung cancer [5], renal cell cancer [6], esophageus cancer [7], liver cancer [8], and gastric cancer [9]. FDA-approved Nivolumab and Pembrolizumab (two fully human IgG4 monoclonal antibodies blocking the programmed death-1 (PD-1) receptor) are considered the mainstay treatment for patients with MGC who failed to respond to chemotherapy [10, 11]. However, debates have recently arisen over the timing of anti-PD-1 antibody administration for late-stage gastric cancer. Pembrolizumab was shown to be nonsuperior to chemotherapy in the first- and second-line treatments in the clinical trials [12, 13]. In contrast, another anti-PD-1 agent called Nivolumab, when combined with chemotherapy as first line, was more effective than the standard treatment in AGC and MGC, irrespective of tumor programmed death ligand-1 (PD-L1) expression [14]. PD-L1 expression and other potential biomarkers, including tumor-infiltrating lymphocyte (TIL), microsatellite instability (MSI), tumor mutation burden (TMB), and Epstein–Barr
virus (EBV), are predictive markers for ICI treatment outcomes in gastric cancer [15–17]. However, in most cases, assessing these potential biomarkers is expensive, time-consuming, or not routinely feasible during therapy. Therefore, they cannot be applied for an upfront selection of patients.

Tumor-induced systemic inflammatory response was confirmed as an effective prognostic biomarker in many cancers [18–23]. The response includes leukocyte, neutrophil, and monocyte counts; neutrophil-to-lymphocyte ratio (NLR); monocyte-to-lymphocyte ratio (MLR); and platelet-to-lymphocyte ratio (PLR). NLR has been recognized as a prognostic predictor of survival in patients undergoing surgery with gastric cancer at the early stage [24] or patients with late stage treated with chemotherapy or Nivolumab monotherapy [21, 25–31]. To our knowledge, however, the predictive value of NLR for MGC patients with anti-PD-1 antibodies in combination with other therapies has not been widely studied. Therefore, it is of interest to investigate whether NLR can predict survival outcomes in patients with MGC treated with anti-PD-1.

Figure 1: Progression-free survival (PFS) (a) and overall survival (OS) (b) in NLR quartile.

Figure 2: (a) Receiver operating characteristic curves for predicting 6-month and 12-month PFS by the neutrophil-to-lymphocyte ratio (AUC areas under the curve are 0.71 and 0.66). (b) AUC value by PFS time.
Table 1: The characteristics of the analyzed patients in different groups.

| Characteristics                        | NLR < 3.23 | NLR ≥ 3.23 | p value |
|----------------------------------------|------------|------------|---------|
| No. patients                           | N           | %          | N       | %          |         |
| Gender n (%)                           |            |            |         |            |         |
| Male                                   | 59         | 72.8%      | 39      | 69.6%      | 0.685   |
| Female                                 | 22         | 27.2%      | 17      | 30.4%      |         |
| Age median = 59 n (%)                  |            |            |         |            |         |
| <59                                    | 35         | 43.2%      | 21      | 37.5%      | 0.505   |
| ≥59                                    | 46         | 56.8%      | 35      | 62.5%      |         |
| PD-L1 n (%)                            |            |            |         |            |         |
| Positive                               | 14         | 17.3%      | 11      | 19.6%      | 0.227   |
| Negative                               | 14         | 17.3%      | 15      | 26.8%      |         |
| Unknown                                | 53         | 65.4%      | 30      | 53.6%      |         |
| ECOG PS n (%)                          |            |            |         |            |         |
| 0                                      | 26         | 32.1%      | 10      | 17.9%      | 0.508   |
| 1                                      | 43         | 53.1%      | 43      | 76.8%      |         |
| ≥2                                     | 12         | 14.8%      | 3       | 5.4%       |         |
| Tumor_location n (%)                   |            |            |         |            |         |
| Cardia                                 | 25         | 30.9%      | 14      | 25.0%      | 0.448   |
| Body/fundus                            | 50         | 61.7%      | 37      | 66.1%      |         |
| Pylorus                                | 6          | 7.4%       | 5       | 8.9%       |         |
| Histological differentiation n (%)     |            |            |         |            |         |
| Poorly                                 | 40         | 49.4%      | 31      | 55.4%      | 0.473   |
| Moderately                             | 37         | 45.7%      | 23      | 41.1%      |         |
| Well                                   | 4          | 4.9%       | 2       | 3.6%       |         |
| No. of metastasis organs n (%)         |            |            |         |            |         |
| <2                                     | 24         | 29.6%      | 11      | 19.6%      | 0.189   |
| ≥2                                     | 57         | 70.4%      | 45      | 80.4%      |         |
| Liver metastasis n (%)                 |            |            |         |            |         |
| Yes                                    | 49         | 60.5%      | 31      | 55.4%      | 0.55    |
| No                                     | 32         | 39.5%      | 25      | 44.6%      |         |
| Smoking_history n (%)                  |            |            |         |            |         |
| Smoke                                  | 30         | 37.0%      | 29      | 51.8%      | 0.088   |
| Never smoked                           | 51         | 63.0%      | 27      | 48.2%      |         |
| Drinking_history n (%)                 |            |            |         |            |         |
| Drink                                  | 38         | 46.9%      | 35      | 62.5%      | 0.073   |
| Never dranked                          | 43         | 53.1%      | 21      | 37.5%      |         |
| Anti-PD-1 treatment line n (%)         |            |            |         |            |         |
| First line                             | 42         | 51.9%      | 24      | 42.9%      | 0.421   |
| Second line                            | 34         | 42.0%      | 30      | 53.6%      |         |
| Third line                             | 5          | 6.2%       | 2       | 3.6%       |         |
| Treatment type n (%)                   |            |            |         |            |         |
| Anti-PD-1 monotherapy                  | 8          | 9.9%       | 7       | 12.5%      | 0.741   |
| Combination therapy                    |            |            |         |            |         |
| Anti-PD-1 plus chemotherapy            | 55         | 67.9%      | 37      | 66.1%      |         |
| Anti-PD-1 plus antiangiogenic therapy  | 18         | 22.2%      | 12      | 21.4%      |         |

ECOG PS: Eastern Cooperative Oncology Group Performance Status; PD-L1: programmed death ligand-1.
2. Patients and Method

2.1. Study Patients. Medical records from MGC patients who received PD-1 inhibitor in the Oncology Department of the Chinese PLA General Hospital between January 2016 and November 2020 were retrospectively reviewed. The study adhered to the Declaration of Helsinki and was approved by the hospital’s ethics committee. Patients who received any PD-L1 inhibitor and anti-CTLA4 treatment were excluded. The inclusion criteria were as follows: (1) pathologically diagnosed MGC, (2) complete clinical characteristics available, (3) at least one measurable lesion and confirmed response outcome, (4) complete blood cell count before the initiation of anti-PD-1 inhibitor, and (5) acquired survival status. All the data was obtained from electronic clinical chart in our oncology department. The baseline NLR was defined as the neutrophil count divided by the lymphocyte count. The receiver operating characteristic analyses for predicting 6-month and 12-month progression-free survival (PFS) by the NLR was applied to identify an appropriate cut-off value for NLR according to previous studies [30]. The patients were then divided into the low NLR group (< cut-off value of NLR) and high NLR group (≥ cut-off value of NLR). The studies involving human participants were reviewed and approved by the ethics committee of the Chinese People’s Liberation Army General Hospital (PLAGH).

2.2. Treatment. PD-1–targeting antibodies included Nivolumab at a dose of 3 mg/kg, Pembrolizumab at 200 mg intravenously, Sintilimab (domestic anti-PD-1 agents) at 200 mg per cycle, or Toripalimab (another anti-PD-1 agent) as a stable 240 mg dosage, which was given alone or followed by cytotoxicity regime or other angiogenesis inhibitors. Angiogenesis inhibitors can be small-molecule tyrosine kinase inhibitors (TKI) such as Apatinib or monoclonal antibodies such as Bevacizumab. The combined regimen was based on the patient’s condition and preference. All the patients signed informed consent for treatment.

2.3. Assessment. The study’s primary end-point was to assess the prognostic significance on progression-free survival (PFS) and overall survival (OS) with different pretreatment NLR levels. PFS was defined from the date of any treatment initiation until the date of either the first progression or death. OS was calculated from the initiation of each line treatment until the date of death due to any cause. Depending on the drug regimen, treatment efficacy was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST). The response was graded into four classes: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Objective response was defined as CR plus PR, while disease control was defined as CR, PR, or SD.

2.4. Statistical Analysis. All statistical analyses were performed using SPSS for Windows version 20.0 (SPSS, Inc., Chicago, IL). The difference of category variables of characteristics among the low NLR group and high NLR was compared by χ² tests. Survival curves of PFS and OS were estimated by the Kaplan–Meier method. The log-rank test was used to compare OS and PFS between groups when the patients were stratified into quartiles based on NLR or the cut-off values. Prognostic factors for OS and PFS were performed by univariate and multivariate analyses. R package survival ROC, Version 1.03, was used to calculate the cut-off of NLR [32]. The level of significance was set to p < 0.05.

3. Result

A total of 137 patients were enrolled in the analysis following the specified criteria. Of these, 98 were males and 39 females, with a median age of 59 years. Among them, 71 patients were administered immunotherapy as a first line while the rest received immunotherapy as the second or further line. 92 patients had received immunotherapy combined with chemotherapy, whereas 45 patients had undertaken immunotherapy alone or with angiogenesis inhibitors. The median neutrophil-to-lymphocyte ratio (NLR) in all patients was 4.65 (range, 0.72–79, 95% CI 3.34-5.96). The median PFS was 5.2 m, and OS was 10.9 m among 137 patients.

Patients were plotted as a cohort by quartiles based on NLR. The significant difference of PFS and OS is shown in the patients’ cohort stratified into quartiles of NLR (p < 0.01; Figure 1). The optimal cut-off value of NLR was 3.23 (AUC = 0.71, p < 0.001) (Figure 2). Patients were divided into two groups: the NLR < 3.23 group (low NLR) and the NLR ≥ 3.23 group (high NLR). A summary of the patients’ characteristics in the NLR < 3.23 group (81 cases) and the NLR ≥ 3.23 group (56 case) is shown in Table 1. None of the clinical features in the two groups was compared with the difference in terms of gender, age, Eastern Cooperative Oncology Group Performance Status (ECOG PS), PD-L1 expression status, primary tumor site, histological differentiation, number of metastatic sites, presence of liver metastasis, smoking and drinking habit, and anti-PD-1 treatment line and type (Table 1).

Table 2: Treatment response in the NLR < 3.23 group and in the NLR ≥ 3.23 group.

| Response   | NLR < 3.23 | NLR ≥ 3.23 | p value |
|------------|------------|------------|---------|
| CR         | 2          | 1          | 1.8%    |
| PR         | 27         | 15         | 26.8%   |
| SD         | 41         | 28         | 50.0%   |
| PD         | 11         | 12         | 21.4%   |
| ORR        |            |            | 0.377   |
| CR+PR      | 29         | 16         | 28.6%   |
| SD+PD      | 52         | 40         | 71.4%   |
| DCR        |            |            | 0.229   |
| CR+PR+SD   | 70         | 44         | 78.6%   |
| PD         | 11         | 12         | 21.4%   |
We recorded an objective response in 29 of 81 patients (35.8%) with 2 complete responses (CR) in the NLR < 3.23 group and 16 out of 56 patients (28.6%) in the NLR ≥ 3.23 group. The confirmed disease control rate (DCR) was 86.4% in the low NLR group and 78.6% in the counterpart group. No statistical difference of ORR and DCR was observed in the two groups (p = 0.377 and p = 0.229, respectively) (Table 2).

As shown in Figure 3, the PFS in the low NLR group was 7.9 months while the PFS in the high NLR group was 3.9 months (HR = 0.42, 95% CI 0.29-0.62, p < 0.001). Similarly, OS was 13.5 months in the low NLR group and 6.3 months in the high NLR group (HR = 0.38, 95% CI, 0.26-0.57, p < 0.001). The risk of death was significantly lowered by 62% in the low NLR group than in the high NLR group. The curves for both groups were well separated over time.

Clinical variables for prognosis prediction were evaluated with univariate and multivariate analyses. Univariate analysis revealed that patients receiving immunotherapy in the first line had significantly higher PFS and OS than patients with immunotherapy in the second line or further line. Anti-PD-1 plus chemotherapy led to longer PFS and OS than ICI monotherapy or with antiangiogenic drugs given to patients (p < 0.05). Patients with ECOC PS ≥ 2 were associated with poorer PFS (HR = 1.96, 95% CI 1.14-3.37, p = 0.012) but not OS (HR = 1.18, 95% CI 0.67-2.08, p = 0.557). High pretreatment NLR was associated with lower PFS and OS. Multivariate analysis suggested that NLR was
a significant and independent prognosis biomarker for PFS and OS (Tables 3 and 4).

4. Discussion

Previous studies had extensively demonstrated that pretreatment NLR is a reliable prognostic marker for metastatic melanoma patients undergoing Ipilimumab or Nivolumab treatment [23, 33]. A meta-analysis including 738 ICI-treated patients with NSCLC or melanoma or advanced GU cancer showed that a high NLR was associated with poorer outcomes [34]. Currently, only two studies focused on NLR changes after Nivolumab monotherapy or baseline NLR prior to Nivolumab for gastric cancer in the third or further lines [26, 28]. Several trials had shown that Nivolumab combined with chemotherapy was superior to chemotherapy alone in the first line concerning PFS and OS [9, 35]. Anti-PD-1 monotherapy or combined therapy had been prevalently applied in the first or second line for AGC and MGC patients. However, anti-PD-1 monotherapy is still not recommended by the National Comprehensive Cancer Network (NCCN) or domestic guidelines. We observed that not all patients were suitable for treatment with anti-PD-1 monotherapy. Due to this, it is necessary to investigate the convenient potential biomarker for the identification of cancer patients who are prescribed with anti-PD-1 in any line or any combination at high risk.

To the best of our knowledge, our study showed for the first time that NLR is an independent predictor of which MGC patients are more likely to benefit from anti-PD-1 treatment. Patients in the low NLR group had a longer survival time than those in the high NLR group, which was consistent with other studies [24, 30, 31, 36–38]. Murakami et al. had reported that the median survival times were 9.1 months in the NLR high group and 17.1 months in NLR low group (p < 0.0001) among patients with unresectable GC. Elevated NLR was also associated with worse DSS (HR, 1.11; 95% CI, 1.08–1.14; p < 0.01) in resectable GC from the study of Wang et al. [39]. A systematic review and meta-analysis also further revealed an association of high neutrophil-lymphocyte ratios with older age, male gender, and lower 5-year overall survival in gastric cancer patients submitted to curative resection [38]. Why NLR is associated immunotherapy outcome may be attributed to the following reasons: inflammatory reactions induced by tumors generate a cancer-related inflammatory microenvironment resistant to the immune monitor [40]. Neutrophils are a systemic inflammatory index because they suppress lymphocytes’ immune activity by producing chemokines and cytokines [41]. This may explain the negative response to immunotherapy when there is a high level of neutrophils. On the other hand, the lymphocyte count represents a measure of lymphocyte infiltration around the tumor tissues, which has already been reported in association with prognosis in solid cancers [42, 43]. A lower NLR stands for relative lymphocyte dominance and reflects the unique properties of favorable inflammatory microenvironment for a subsequent antitumor immunologic reaction. Therefore, in view of these considerations, we suggest that patients with low NLR are prone to have better inflammatory responses and prognoses. Thus, careful attention must be paid when PD-1 inhibitors are given to patients with high NLR levels.

The cut-off value in our study was in accordance with ROC analysis by six-month survival. The optimal candidate cut-off value was 3.23 for NLR. The values of cut-off NLR are from 2.5 to 4 reported in gastric cancer among other studies [27, 36, 37, 44]. However, there was no standard for selecting the cut-off value. Some studies had applied the receiver operating characteristic (ROC) curve for estimating the cut-off value [21, 26, 28, 45–47]. The median value of NLR was also used as the cut-off of NLR in the study [24, 48, 49]. Furthermore, in our study, we found that NLR had the highest area under the curve for six-month other than one-year survival. In contrast, NLR had the highest area under the curve for one year among patients with unresectable GC in this study [30]. So it is of controversy, and we

| Variable category | Category | HR (95% CI) | p value | HR (95% CI) | p value |
|-------------------|----------|-------------|---------|-------------|---------|
| Gender            | Female versus male | 0.99 (0.64-1.52) | 0.955 | 0.82 (0.48-1.39) | 0.468 |
| Age               | ≥59 versus <59 | 1.29 (0.87-1.89) | 0.199 | 1.34 (0.83-2.18) | 0.230 |
| ECOG              | ≥2 versus 0-1 | 1.18 (0.67-2.08) | 0.557 | 1.58 (0.85-2.93) | 0.146 |
| Tumor_location    | Cardia versus body/fundus versus pylorus | 0.89 (0.70-1.12) | 0.103 | 0.99 (0.74-1.33) | 0.968 |
| Histological differentiation | Poorly versus moderately and well | 1.92 (1.29-2.86) | 0.001 | 1.89 (1.21-2.94) | 0.005 |
| No. of metastasis organs | ≥2 versus <2 | 1.39 (0.87-2.20) | 0.156 | 1.15 (0.71-1.87) | 0.564 |
| Liver metastasis  | Yes versus no | 0.84 (0.57-1.25) | 0.396 | 0.88 (0.54-1.41) | 0.584 |
| Smoking_history   | Smoke versus never smoked | 1.40 (0.96-2.06) | 0.077 | 1.38 (0.78-2.43) | 0.271 |
| Drinking_history  | Drink versus never drinked | 0.73 (0.49-1.07) | 0.110 | 0.73 (0.42-1.26) | 0.259 |
| Anti-PD-1 therapy line | First line versus second line and third line | 0.551 (0.38-0.80) | 0.002 | 0.64 (0.39-1.06) | 0.086 |
| Treatment type    | Anti-PD-1 plus chemotherapy versus anti-PD-1 monotherapy or antiangiogenesis | 0.49 (0.33-0.73) | <0.001 | 0.73 (0.43-1.24) | 0.249 |
| Baseline NLR      | <3.23 versus ≥3.23 | 0.38 (0.26-0.57) | <0.001 | 0.34 (0.22-0.52) | <0.001 |

CI: confidence interval; ECOG PS: Eastern Cooperative Oncology Group Performance Status; NLR: neutrophil-to-lymphocyte ratio; HR: hazard ratio.
adopted the cut-off value with highest area under curve in ROC analysis in our study according to previous reports. Interestingly, in our study, the low NLR group had a nonsuperior disease control rate (DCR) and ORR than the high NLR group ($p > 0.05$). A few clinical studies have shown the association between NLR and response to chemotherapy or immunotherapy in solid cancers [50]. In contrast with our findings, a study found that the low NLR group had a significantly higher disease control rate than the high NLR group in metastatic advanced gastric cancer response to chemotherapy [49]. However, although there was no statistical difference in ORR and DCR in our study, ORR was numerically higher in the low NLR group than the high NLR group (35.8% vs. 28.6%). The current study adds an additional component to our understanding of the predictive value of NLR in immunotherapy.

Univariate and multivariate analyses also showed that NLR is an independent prognostic biomarker for MGC patients exposed to anti-PD-1 therapy. Nowadays, PD-L1 expression, TMB or TIL, and microsatellite instability (MSI) have been identified as potential biomarkers in many solid tumors [51–59]. However, TMB and TIL evaluations are not routinely performed in clinical practice. Instead, NLR can be tested with a standard blood test and is particularly advantageous as a biomarker because of its availability and cost-effectiveness.

Limitations of this study included the small sample size with retrospective design and absence of an external validation series for the cut-off value of PLR. This observational study was based on a single institution which may cause selection bias. It further stimulates us to conduct more studies for the validation of predictive value of NLR for the response to treatment with the checkpoint inhibitors in patients with MGC.

5. Conclusion

In summary, we showed that pretreatment NLR is significantly and independently associated with PFS and OS in patients with MGC receiving PD-1 inhibitors. Therefore, NLR should be considered as an aid for decisions on treatment strategy and as an effective prognostic predictor.

Data Availability

Data are provided in the Supplementary Information files that were submitted alongside the manuscript.

Disclosure

An earlier version of this manuscript has been presented as an abstract in the Journal of Clinical Oncology according to the following link: doi:10.1200/JCO.2021.39.15_suppl.e16075.

Conflicts of Interest

There are no conflicts of interest.

Authors’ Contributions

Miaomiao Gou was responsible for writing the manuscript; Tongtong Qu, Zhikuan Wang, and Huan Yan took charge of the data collection; Yong Zhang and Guanghai Dai was responsible for supervision. All authors read and approved the final manuscript. Guanghai Dai and Yong Zhang are co-corresponding authors. Miaomiao Gou and Zhikuan Wang are co-first authors.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (No. 31671298) and the National Key Research and Development Program of China (2017YFC1308902).

Supplementary Materials

The supplementary data are the complete clinical profiles of the patients involved in the study. (Supplementary Materials)

References

[1] W. Chen, R. Zheng, P. D. Baade et al., “Cancer statistics in China, 2015,” CA: a Cancer Journal for Clinicians, vol. 66, no. 2, pp. 115–132, 2016.
[2] T. Irino, H. Takeuchi, M. Terashima, T. Wakai, and Y. Kitagawa, “Gastric cancer in Asia: unique features and management,” American Society of Clinical Oncology Educational Book, vol. 37, no. 37, pp. 279–291, 2017.
[3] Y. Yamada, K. Higuchi, K. Nishikawa et al., “Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer,” Annals of Oncology, vol. 26, no. 1, pp. 141–148, 2015.
[4] K. Nakamura and R. Okuyama, “Immunotherapy for advanced melanoma: current knowledge and future directions,” Journal of Dermatological Science, vol. 83, no. 2, pp. 87–94, 2016.
[5] S. Gettinger, N. A. Rizvi, L. Q. Chow et al., “Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 34, no. 25, pp. 2980–2987, 2016.
[6] F. Peinemann, S. Unverzagt, A. V. Hadjinicolaou, and I. Moldenhauer, “Immunotherapy for metastatic renal cell carcinoma: a systematic review,” Journal of Evidence-Based Medicine, vol. 12, no. 4, pp. 253–262, 2019.
[7] T. Kojima, K. Muro, E. Francois et al., “Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase III KEYNOTE-181 study,” Journal of Clinical Oncology, vol. 37, 4_suppl, p. 2, 2019.
[8] R. S. Finn, B. Y. Ryoo, P. Merle et al., “Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial,” Journal of Clinical Oncology, vol. 38, no. 3, pp. 193–202, 2020.
[9] N. Boku, M. H. Ryu, K. Kato et al., “Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim
results of a randomized, phase II trial (ATTRACTION-4),”
*Annals of Oncology*, vol. 30, no. 2, pp. 250–258, 2019.

[10] C. S. Fuchs, T. Doi, R. W. Jang et al., “Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial,” *JAMA Oncology*, vol. 4, no. 5, article e180013, 2018.

[11] Y. K. Kang, N. Boku, T. Satoh et al., “Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial,” *Lancet*, vol. 390, no. 10111, pp. 2461–2471, 2017.

[12] K. Shitara, M. Özgüro, Y. J. Bang et al., “Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial,” *Lancet*, vol. 392, no. 10142, pp. 123–133, 2018.

[13] J. Tabernero, E. van Cutsem, Y.-J. Bang et al., “Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: the phase III KEYNOTE-062 study,” *Journal of Clinical Oncology*, vol. 37, article LBA4007, 2019.

[14] N. Boku, M. H. Ryu, D. Oh et al., “LIBA7_PR - nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastro-esophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study,” *Annals of Oncology*, vol. 31, suppl_4, pp. S1142–S1215, 2020.

[15] S. T. Kim, R. Cristescu, A. J. Bass et al., “Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer,” *Nature Medicine*, vol. 24, no. 9, pp. 1449–1458, 2018.

[16] F. Wang, X. L. Wei, F. H. Wang et al., “Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432,” *Annals of Oncology*, vol. 30, no. 9, pp. 1479–1486, 2019.

[17] H. Cai, C. Jing, X. Chang et al., “Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing,” *Journal of Translational Medicine*, vol. 17, no. 1, p. 189, 2019.

[18] X. Xie, K. J. Luo, Y. Hu, J. Y. Wang, and J. Chen, “Prognostic value of preoperative platelet-lymphocyte and neutrophil-lymphocyte ratio in patients undergoing surgery for esophageal squamous cell cancer,” *Diseases of the Esophagus*, vol. 29, no. 1, pp. 79–85, 2016.

[19] H. S. Kim and J. H. Ku, “Systemic inflammatory response based on neutrophil-to-lymphocyte ratio as a prognostic marker in bladder cancer,” *Disease Markers*, vol. 2016, Article ID 8345286, 12 pages, 2016.

[20] K. M. Sarraf, E. Belcher, E. Raevsky, A. G. Nicholson, P. Goldstraw, and E. Lim, “Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer,” *The Journal of Thoracic and Cardiovascular Surgery*, vol. 137, no. 2, pp. 425–428, 2009.

[21] K. Miyatani, H. Saito, Y. Kono et al., “Combined analysis of the pre- and postoperative neutrophil-lymphocyte ratio predicts the outcomes of patients with gastric cancer,” *Surgery Today*, vol. 48, no. 3, pp. 300–307, 2018.

[22] L. Chen, F. Zhang, X. G. Sheng, S. Q. Zhang, Y. T. Chen, and B. W. Liu, “Peripheral platelet/lymphocyte ratio predicts lymph node metastasis and acts as a superior prognostic factor for cervical cancer when combined with neutrophil-lymphocyte,” *Medicine (Baltimore)*, vol. 95, no. 32, article e4381, 2016.

[23] M. Capone, D. Giannarelli, D. Mallardo et al., “Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab,” *Journal for Immunotherapy of Cancer*, vol. 6, no. 1, p. 74, 2018.

[24] Y. Wang, J. Zhai, T. Zhang, S. Han, Y. Zhang, and X. Yao, “Tumor-associated neutrophils can predict lymph node metastasis in early gastric cancer,” *Frontiers in Oncology*, vol. 10, article 570113, 2020.

[25] T. Hirahara, T. Arigami, S. Yanagita et al., “Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer,” *BMC Cancer*, vol. 19, no. 1, p. 672, 2019.

[26] Y. Ota, D. Takahari, T. Suzuki et al., “Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival,” *Cancer Chemotherapy and Pharmacology*, vol. 85, no. 2, pp. 265–272, 2020.

[27] Y. Li, C. Wang, M. Xu et al., “Preoperative NLR for predicting survival rate after radical resection combined with adjuvant immunotherapy with CIK and postoperative chemotherapy in gastric cancer,” *Journal of Cancer Research and Clinical Oncology*, vol. 143, no. 5, pp. 861–871, 2017.

[28] T. Yamada, T. Hayashi, Y. Inokuchi et al., “Impact of the neutrophil-to-lymphocyte ratio on the survival of patients with gastric cancer treated with nivolumab monotherapy,” *Targeted Oncology*, vol. 15, no. 3, pp. 317–325, 2020.

[29] J. Sun, X. Chen, P. Gao et al., “Can the neutrophil to lymphocyte ratio be used to determine gastric cancer treatment outcomes? A systematic review and meta-analysis,” *Disease Markers*, vol. 2016, Article ID 7862469, 10 pages, 2016.

[30] Y. Murakami, H. Saito, S. Shimizu et al., “Neutrophil-to-lymphocyte ratio as a prognostic indicator in patients with Unresectable gastric cancer,” *Anticancer Research*, vol. 39, no. 5, pp. 2583–2589, 2019.

[31] Y. Zhang, J. J. Lu, Y. P. Du, C. X. Feng, L. Q. Wang, and M. B. Chen, “Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer,” *Medicine*, vol. 97, no. 12, article e0144, 2018.

[32] P. J. Heagerty, T. Lumley, and M. S. Pepe, “Time-dependent ROC curves for censored survival data and a diagnostic marker,” *Biometrics*, vol. 56, no. 2, pp. 337–344, 2000.

[33] M. R. Cassidy, R. E. Wolchok, J. Zheng et al., “Neutrophil to lymphocyte ratio is associated with outcome during ilipilumab treatment,” *eBioMedicine*, vol. 18, pp. 56–61, 2017.

[34] D. B. Sacdalan, J. A. Lucero, and D. L. Sacdalan, “Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis,” *Oncotargets and Therapy*, vol. Volume 11, pp. 955–965, 2018.

[35] M. Moehler, K. Shitara, M. Garrido et al., “Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: first results of the CheckMate 649 study,” *Annals of Oncology*, vol. 31, article S1191, Suppl 4, 2020.
[36] M. Magdy, T. Hussein, A. Ezzat, and A. Gaballah, “Pre-treatment peripheral neutrophil-lymphocyte ratio as a prognostic marker in gastric cancer,” *Journal of Gastrointestinal Cancer*, vol. 50, no. 4, pp. 763–768, 2019.

[37] H. Shimada, N. Takiguchi, O. Kainuma et al., “High preoperative neutrophil-to-lymphocyte ratio predicts poor survival in patients with gastric cancer,” *Gastric Cancer*, vol. 13, no. 3, pp. 170–176, 2010.

[38] D. J. Szor, A. R. Dias, M. A. Pereira et al., “Prognostic role of neutrophil/lymphocyte ratio in resected gastric cancer: a systematic review and meta-analysis,” *Clinics*, vol. 73, p. e360, 2018.

[39] S. C. Wang, J. F. Chou, V. E. Strong, M. F. Brennan, M. Capanu, and D. G. Coit, “Pretreatment neutrophil to lymphocyte ratio independently predicts disease-specific survival in resectable gastroesophageal junction and gastric adenocarcinoma,” *Annals of Surgery*, vol. 263, no. 2, pp. 292–297, 2016.

[40] G. Liccardi and F. Pentimalli, “Cancer, immunity and inflammation. Report from the CDD Cambridge Conferences 2018 and 2019,” *Cell Death & Disease*, vol. 10, no. 11, p. 798, 2019.

[41] A. D. Gregory and A. McGarry Houghton, “Tumor-associated neutrophils: new targets for cancer therapy,” *Cancer Research*, vol. 71, no. 7, pp. 2411–2416, 2011.

[42] A. Kawata, Y. Une, M. Hosokawa, J. Uchino, and H. Kobayashi, “Tumor-infiltrating lymphocytes and prognosis of hepatocellular carcinoma,” *Japanese Journal of Clinical Oncology*, vol. 22, no. 4, pp. 256–263, 1992.

[43] P. Fogar, C. Sperti, D. Basso et al., “Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome,” *Pancreas*, vol. 32, no. 1, pp. 22–28, 2006.

[44] R. Miyamoto, S. Inagawa, N. Sano, S. Tadano, S. Adachi, and M. Yamamoto, “The neutrophil-to-lymphocyte ratio (NLR) predicts short-term and long-term outcomes in gastric cancer patients,” *European Journal of Surgical Oncology*, vol. 44, no. 5, pp. 607–612, 2018.

[45] Q. Deng, B. He, X. Liu et al., “Prognostic value of pre-operative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model,” *Journal of Translational Medicine*, vol. 13, no. 1, p. 66, 2015.

[46] S. Song, C. Li, S. Li, H. Gao, X. Lan, and Y. Xue, “Derived neutrophil to lymphocyte ratio and monocyte to lymphocyte ratio may be better biomarkers for predicting overall survival of patients with advanced gastric cancer,” *Oncotherapy*, vol. 10, pp. 3145–3154, 2017.

[47] H. Tanaka, T. Tamura, T. Toyokawa et al., “Clinical relevance of postoperative neutrophil-to-lymphocyte ratio (NLR) to recurrence after adjuvant chemotherapy of S-1 for gastric cancer,” *Anticancer Research*, vol. 38, no. 6, pp. 3745–3751, 2018.

[48] H. Jin, G. Zhang, X. Liu et al., “Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy,” *World Journal of Surgical Oncology*, vol. 11, no. 1, p. 112, 2013.

[49] I. R. Cho, J. C. Park, C. H. Park et al., “Pre-treatment neutrophil to lymphocyte ratio as a prognostic marker to predict chemotherapy response and survival outcomes in metastatic advanced gastric cancer,” *Gastric Cancer*, vol. 17, no. 4, pp. 703–710, 2014.

[50] M. Ameratunga, M. Chénard-Pointier, I. Moreno Candilejo et al., “Neutrophil-to-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors,” *European Journal of Cancer*, vol. 89, pp. 56–63, 2018.

[51] A. M. Goodman, S. Kato, L. Bazhenova et al., “Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers,” *Molecular Cancer Therapeutics*, vol. 16, no. 11, pp. 2598–2608, 2017.

[52] M. Greally, J. F. Chou, W. K. Chatila et al., “Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer,” *Clinical Cancer Research*, vol. 25, no. 20, pp. 6160–6169, 2019.

[53] A. Marabelle, M. Fakh, J. Lopez et al., “Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study,” *The Lancet Oncology*, vol. 21, no. 10, pp. 1353–1365, 2020.

[54] K. Kato, J.-M. Sun, M. A. Shah et al., “LBAA8_PR pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: the phase 3 KEYNOTE-590 study,” *Annals of Oncology*, vol. 31, pp. S1192–S1193, 2020.

[55] M. A. Shah, T. Kojima, D. Hochhauser et al., “Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study,” *JAMA Oncology*, vol. 5, no. 4, pp. 546–550, 2019.

[56] D. T. le, T. W. Kim, E. van Cutsem et al., “Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164,” *Journal of Clinical Oncology*, vol. 38, no. 1, pp. 11–19, 2020.

[57] D. T. le, J. N. Uram, H. Wang et al., “PD-1 blockade in tumors with mismatch-repair deficiency,” *The New England Journal of Medicine*, vol. 372, no. 26, pp. 2509–2520, 2015.

[58] N. Lee, L. R. Zakka, M. C. Mihm, and T. Schatton, “Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy,” *Pathology*, vol. 48, no. 2, pp. 177–187, 2016.

[59] M. Yi, D. Jiao, H. Xu et al., “Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors,” *Molecular Cancer*, vol. 17, no. 1, p. 129, 2018.